New York, 28 Feb. 2022 (GLOBE NEWSWIRE) — Reportlinker.com announces the publication of the report “Global Virology Specimen Collection Market By Sample, By Product Type, By Regional Outlook, Industry Analysis Report and Forecast, 2021 -2027” – https://www.reportlinker.com/p06241038/?utm_source=GNW
Microbiology and pathology are often confused with virology. Viruses quickly evolved into tools for analyzing basic biochemical processes in cells during the early years of virology, which relied on advances in chemical and physical sciences. Viruses have traditionally been viewed as pathogens that need to be eradicated or controlled.
After the initial operational definition of a virus as a filterable agent, researchers attempted to find the characteristics of viruses that distinguished them from other microbes. For this purpose, all viruses have the same defining characteristic that they are obligate intracellular molecular parasites. The fact that viruses do not reproduce by binary fission, which is a mode of asexual reproduction in which pre-existing cells divide into two identical daughter cells, is a second crucial attribute of viruses.
In February 2020, for example, Becton, Dickinson partnered with Babson Diagnostics to develop low-volume blood collection systems for retail pharmacies. They have partnered to make blood testing more accessible and convenient by integrating BD’s blood collection device with Babson’s automated sample handling and analysis capabilities.
Molecular diagnostic companies are encouraged to create a collection of bacterial and viral samples along with diagnostic solutions that beneficially impact market growth through increased funding from public and private organizations. For example, the U.S. Department of Defense and the U.S. Department of Health and Human Services (HHS) awarded Hologic Inc. $7.6 million in July 2020 to improve the manufacturing of waste collection and processing consumables. specimens for SARS-CoV-2 testing.
COVID-19 Impact Analysis
The outbreak of the COVID-19 pandemic has impacted the way medical treatment is delivered around the world. Due to the increased demand caused by the increasing prevalence of COVID-19 hospitalizations, several hospitals and departments have redefined their strategies for managing COVID-19 patients. Curfews and lockdowns have been imposed around the world as a result of the COVID-19 pandemic, stopping blood donations, reducing/cancelling collection campaigns and reducing the demand for blood donations.
Moreover, the increased frequency of viral infections such as SARS-CoV-2, AIDS, influenza, EBOLA, Zika virus and STDs is fueling the demand for efficient collection of virological samples. According to the World Health Organization (WHO) (July 2021), at the end of 2020, there were approximately 37.7 million (30.2-45.1 million) people living with HIV, including nearly two-thirds (25.4 million) living in the African Region. In 2020, 680,000 (480,000 to 1.0 million) people will have died of HIV-related causes, while 1.5 million (1.0 to 2.0 million) will have contracted the virus. I
Market Growth Factors:
Increase in viral diseases with the emergence of new pathogens
The Zika and Babesia epidemic has become a very critical problem for humanity. The Zika virus is deadly enough to cause serious harm to people and can also lead to death in some cases. On the other hand, Babesia virus is commonly found in dogs. However, some species of the Babesia virus can enter the human body. The identification of these viruses is a crucial issue. Moreover, the fact that these viruses as well as their mutations would be included in virology sample collection assays underscores the need for new virology sample collection technologies, consumables and instruments.
Growing potential of virological sample collection techniques
Collecting virological samples is an expensive sample collection measure. However, due to their increasing available budgets and growing healthcare infrastructure, emerging countries present potential opportunities for virus sample collection companies. Due to rising income levels, heightened health awareness and increasing incidence of lifestyle disorders, people are demanding high demands for virological testing. In India, ELISA is currently commonly used, while NAT has limited penetration.
Market restraining factors:
Increased spending on virus sample collection technologies
New technologies are widely used in high-income countries and will be effectively adopted in middle- and low-income countries in the coming years, due to an increase in blood donations, awareness of blood safety and health spending around the world. Many developing countries, such as India and China, currently rely on ELISA. This is a significant impediment to NAT’s current growth in the virus sample collection business. Due to the expensive nature of sophisticated tests, less efficient tests such as the first generation ELISA are used more frequently. Despite its shortcomings, this test is widely used around the world.
Example of Outlook
Based on sample, the virology sample collection market is divided into blood sample, nasopharyngeal sample, throat sample, nasal sample, cervical sample, oral sample and others. Samples. In 2020, the nasal specimens segment followed nasopharyngeal specimens in achieving the second largest revenue share of the virology specimen collection market. The increased growth of this segment is attributed to the increasing prevalence of contagious viral infections across the globe, such as the upsurge of Omicron virus. Due to the increasing number of patients infected with this mutant of the new coronavirus, the demand for testing nasal samples has increased.
Product Type Outlook
On the basis of product type, the virology specimen collection market is segmented into blood collection kits, specimen collection tubes, viral transport media and swabs. In 2020, the viral transport media segment dominated the virology sample collection market by accounting for the largest share of market revenue. The increased growth of this segment is due to the growing awareness among people about blood donation. Due to the large number of people donating blood, the need for virological transport is increasing.
Based on region, the Virology Specimen Collection Market is analyzed across North America, Europe, APAC, and LAMEA. In 2020, North America led the world by acquiring the largest share of virus sample collection market revenue. The largest share of the region’s revenue in the market is attributed to the region’s robust healthcare infrastructure. The clinics, hospitals and other health care institutes in North American countries are equipped with the latest advanced technologies in health care.
The market research report covers the analysis of major market players. Key companies profiled in the report are Trinity Biotech Plc, Thermo Fisher Scientific, Inc., Becton, Dickinson and Company, DiaSorin SpA, Vircell SL, Quidel Corporation, Titan Biotech Ltd., Puritan Medical Products, Copan Italia spa, and Hardy Diagnostics.
Strategies deployed in Virology Specimen Collection Market
May-2021: Quidel has entered into a retail partnership with Walgreens, an American company that operates the second-largest drugstore chain. Through this partnership, the two companies will jointly bring Quidel’s QuickVue® At-Home OTC non-prescription COVID-19 test to market. The partnership was intended to accelerate in-store availability and over-the-counter sales of QuickVue At-Home OTC COVID-19 antigen tests.
Dec-2020: Quidel has received Emergency Use Authorization (EUA) (FDA) clearance from the United States Food and Drug Administration. Additionally, in order to commercialize its Solana SARS-CoV-2 assay, an isothermal Reverse Transcriptase – Helicase-Dependent Amplification (RT-HDA) assay for the qualitative detection of SARS-CoV-2 nucleic acid in the nasopharynx (NP ) and nasal swab (NS) specimens in viral transport media from patients suspected of COVID-19 by their healthcare provider.
March 2020: BD (Becton, Dickinson and Business) has formed a partnership with BioMedomics, a point-of-care diagnostics company. Following this partnership, the two companies have launched a new point-of-care test. Additionally, the test can detect antibodies produced by the body in response to the coronavirus in the blood.
Apr-2019: BD (Becton, Dickinson, and Business), a leading global medical technology company, received CE-IVD Certification for the BD FACSDuetTM Automated Flow Cytometry System. With this, the company would increase the productivity and throughput of their laboratory by using the BD FACSDuet system to replace manual operations with automated operations that are traceable and can be automatically transmitted and documented in the laboratory information system, providing a thorough audit trail.
Scope of the study
Market Segments Covered in the Report:
• Nasopharyngeal samples
• Throat samples
• Cervical specimens
• Nasal samples
• Blood samples
• Oral samples, and
By product type
• Viral transport media
• Sample collection tubes
• Blood collection kits and
• North America
o United States
o Rest of North America
o United Kingdom
o Rest of Europe
• Asia Pacific
o South Korea
o Rest of Asia-Pacific
o Saudi Arabia
o South Africa
o Rest of the LAMEA
• Trinity Biotech Plc
• Thermo Fisher Scientific, Inc.
• Becton, Dickinson and company
• DiaSorin SpA
• Vircell SL
• Quidel Corporation
• Titan Biotech Ltd.
• Puritan medical products
• the Copan Italia spa
• Hardy Diagnostics
• Comprehensive coverage
• The largest number of tables and figures on the market
• Subscription-based model available
• Best price guaranteed
• Support for after-sales research provided with 10% free customization
Read the full report: https://www.reportlinker.com/p06241038/?utm_source=GNW
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.